2023
Role of metformin in the management of type 2 diabetes: recent advances.
Gonzalez-Lopez C, Wojeck B. Role of metformin in the management of type 2 diabetes: recent advances. Polish Archives Of Internal Medicine 2023, 133 PMID: 37317976, DOI: 10.20452/pamw.16511.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 2FemaleGlucoseHumansHypoglycemic AgentsInsulin ResistanceMetforminObesitySodium-Glucose Transporter 2 InhibitorsConceptsType 2 diabetesAntidiabetic medicationsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsCardio-renal protectionCotransporter 2 inhibitorsFirst-line agentsFirst-line therapyPolycystic ovary syndromeRole of metforminRisk of hypoglycemiaTreatment of obesityManagement of diabetesBlood glucose levelsMechanism of actionInitial therapyWay diabetesGestational diabetesOvary syndromeHeart failureRenal diseaseInsulin resistanceInsulin sensitivityReceptor agonist
2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
Wojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HK. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep And Breathing 2022, 27: 669-672. PMID: 35596030, PMCID: PMC10212814, DOI: 10.1007/s11325-022-02594-2.Peer-Reviewed Original ResearchMeSH KeywordsBridged Bicyclo Compounds, HeterocyclicCardiovascular DiseasesDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedSleep Apnea, ObstructiveSodium-Glucose Transporter 2 InhibitorsConceptsObstructive sleep apneaIncident obstructive sleep apneaAtherosclerotic CV diseaseVERTIS CVSleep apneaMultivariable Cox proportional hazards regression modelsIncidence of OSACox proportional hazards regression modelBaseline obstructive sleep apneaMajor adverse CV eventsProportional hazards regression modelsCV outcome trialsEffect of ertugliflozinInvestigator-reported eventsVERTIS-CV trialAdverse CV eventsSleep apnea syndromeRelative risk reductionHazards regression modelsType 2 diabetesCV eventsCV diseasePrimary endpointInhibitor empagliflozinOutcome trials
2021
Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study.
Ding Q, Qin L, Wojeck B, Inzucchi SE, Ibrahim A, Bravata DM, Strohl KP, Yaggi HK, Zinchuk AV. Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study. Annals Of The American Thoracic Society 2021, 18: 2067-2078. PMID: 34185617, PMCID: PMC8641817, DOI: 10.1513/annalsats.202012-1556oc.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 2HumansMalePhenotypePolysomnographySeverity of Illness IndexSleep Apnea, ObstructiveConceptsApnea-hypopnea indexObstructive sleep apneaPolysomnographic phenotypeIncident T2DMRisk of T2DMPredictive valueSleep apneaBlood glucoseRisk factorsCardiovascular diseaseMild obstructive sleep apneaIncident type 2 diabetesMultivariable-adjusted regression modelsCox proportional hazards regressionNew physician diagnosisT2DM risk predictionIncident cardiovascular diseaseIncident type 2Body mass indexProportional hazards regressionT2DM risk factorsBehavioral risk factorsType 2 diabetesMale veteran populationRisk regression modelsResponse to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Neeland IJ, Kasai T, Inzucchi SE, Wojeck BS, Yaggi HK, Johansen OE. Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015. Diabetes Care 2021, 44: e137-e138. PMID: 34016610, PMCID: PMC8247494, DOI: 10.2337/dci21-0009.Commentaries, Editorials and Letters
2020
The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020, 43: 3007-3015. PMID: 33004464, PMCID: PMC7770278, DOI: 10.2337/dc20-1096.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaRenal outcomesOSA statusSleep apneaNew-onset obstructive sleep apneaMultivariable-adjusted Cox regression modelsBaseline obstructive sleep apneaMajor adverse CV eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEImpact of empagliflozinPlacebo-adjusted reductionsAdverse CV eventsEffect of empagliflozinHeart failure hospitalizationSystolic blood pressureCox regression modelStandard of careCV deathCV eventsCV outcomesEmpagliflozin treatmentEMPA-REGRenal eventsCV disease